Spago Nanomedical AB (publ) (SPAGO.ST)
SEK 0.22
(9.5%)
SEK 0.22
(9.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.66 Million SEK | 32.64% |
| 2022 | 8.79 Million SEK | 29.14% |
| 2021 | 6.81 Million SEK | 116.53% |
| 2020 | 3.14 Million SEK | 8.15% |
| 2019 | 2.9 Million SEK | -29.0% |
| 2018 | 4.09 Million SEK | 7.5% |
| 2017 | 3.81 Million SEK | -53.63% |
| 2016 | 8.21 Million SEK | -11.9% |
| 2015 | 9.32 Million SEK | -52.23% |
| 2014 | 19.52 Million SEK | -0.81% |
| 2013 | 19.68 Million SEK | 73.35% |
| 2012 | 11.35 Million SEK | -8.57% |
| 2011 | 12.42 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 7.46 Million SEK | 3.81% |
| 2024 Q1 | 7.19 Million SEK | -38.34% |
| 2023 Q3 | 5.66 Million SEK | 42.22% |
| 2023 FY | 11.66 Million SEK | 32.64% |
| 2023 Q4 | 11.66 Million SEK | 105.82% |
| 2023 Q2 | 3.98 Million SEK | -45.43% |
| 2023 Q1 | 7.3 Million SEK | -16.96% |
| 2022 FY | 8.79 Million SEK | 29.14% |
| 2022 Q3 | 4.28 Million SEK | -66.78% |
| 2022 Q2 | 12.89 Million SEK | 125.52% |
| 2022 Q1 | 5.71 Million SEK | -16.09% |
| 2022 Q4 | 8.79 Million SEK | 105.44% |
| 2021 FY | 6.81 Million SEK | 116.53% |
| 2021 Q2 | 7.07 Million SEK | 104.95% |
| 2021 Q3 | 7.04 Million SEK | -0.4% |
| 2021 Q4 | 6.81 Million SEK | -3.33% |
| 2021 Q1 | 3.45 Million SEK | 9.73% |
| 2020 Q3 | 3.05 Million SEK | 4.41% |
| 2020 Q1 | 4.12 Million SEK | 41.63% |
| 2020 Q4 | 3.14 Million SEK | 2.91% |
| 2020 FY | 3.14 Million SEK | 8.15% |
| 2020 Q2 | 2.92 Million SEK | -28.93% |
| 2019 FY | 2.9 Million SEK | -29.0% |
| 2019 Q1 | 6.36 Million SEK | 55.31% |
| 2019 Q2 | 4.02 Million SEK | -36.73% |
| 2019 Q3 | 6.02 Million SEK | 49.73% |
| 2019 Q4 | 2.9 Million SEK | -51.74% |
| 2018 Q3 | 3.58 Million SEK | -33.15% |
| 2018 FY | 4.09 Million SEK | 7.5% |
| 2018 Q4 | 4.09 Million SEK | 14.44% |
| 2018 Q2 | 5.35 Million SEK | 73.24% |
| 2018 Q1 | 3.09 Million SEK | -18.89% |
| 2017 Q1 | 8.56 Million SEK | 4.25% |
| 2017 FY | 3.81 Million SEK | -53.63% |
| 2017 Q3 | 9.22 Million SEK | 3.18% |
| 2017 Q4 | 3.81 Million SEK | -58.67% |
| 2017 Q2 | 8.93 Million SEK | 4.31% |
| 2016 Q1 | 8.08 Million SEK | -13.36% |
| 2016 FY | 8.21 Million SEK | -11.9% |
| 2016 Q4 | 8.21 Million SEK | 4.82% |
| 2016 Q3 | 7.84 Million SEK | -9.7% |
| 2016 Q2 | 8.68 Million SEK | 7.42% |
| 2015 Q2 | 19.89 Million SEK | -1.92% |
| 2015 Q1 | 20.28 Million SEK | 3.85% |
| 2015 FY | 9.32 Million SEK | -52.23% |
| 2015 Q4 | 9.32 Million SEK | -52.89% |
| 2015 Q3 | 19.8 Million SEK | -0.44% |
| 2014 Q1 | 21.2 Million SEK | 7.69% |
| 2014 Q4 | 19.52 Million SEK | -0.05% |
| 2014 FY | 19.52 Million SEK | -0.81% |
| 2014 Q2 | 21.39 Million SEK | 0.9% |
| 2014 Q3 | 19.53 Million SEK | -8.68% |
| 2013 Q2 | 7.57 Million SEK | 1.51% |
| 2013 FY | 19.68 Million SEK | 73.35% |
| 2013 Q1 | 7.46 Million SEK | -34.3% |
| 2013 Q3 | 8.29 Million SEK | 9.52% |
| 2013 Q4 | 19.68 Million SEK | 137.33% |
| 2012 FY | 11.35 Million SEK | -8.57% |
| 2012 Q3 | 19.91 Million SEK | 0.0% |
| 2012 Q4 | 11.35 Million SEK | -42.97% |
| 2011 FY | 12.42 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -25.046% |
| Amniotics AB (publ) | 10.54 Million SEK | -10.629% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -163.624% |
| BioArctic AB (publ) | 139.5 Million SEK | 91.636% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.255% |
| Genovis AB (publ.) | 98.04 Million SEK | 88.1% |
| LIDDS AB (publ) | 3.75 Million SEK | -210.65% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 90.589% |
| OncoZenge AB (publ) | 1.69 Million SEK | -586.757% |
| Saniona AB (publ) | 86.08 Million SEK | 86.446% |
| Simris Alg AB (publ) | 148.93 Million SEK | 92.166% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 71.443% |
| AcouSort AB (publ) | 10.37 Million SEK | -12.43% |
| Active Biotech AB (publ) | 13.4 Million SEK | 12.925% |
| Camurus AB (publ) | 414.81 Million SEK | 97.187% |
| Cantargia AB (publ) | 54.97 Million SEK | 78.774% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -204.013% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 36.909% |
| Mendus AB (publ) | 51.22 Million SEK | 77.222% |
| Kancera AB (publ) | 17.97 Million SEK | 35.098% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -0.856% |
| Lipum AB (publ) | 7.53 Million SEK | -54.789% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -126.212% |
| NextCell Pharma AB | 13.68 Million SEK | 14.764% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 97.58% |
| Xintela AB (publ) | 14.01 Million SEK | 16.746% |
| Ziccum AB (publ) | 6.38 Million SEK | -82.655% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 15.275% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -394.616% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 39.115% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 83.761% |
| CombiGene AB (publ) | 4.15 Million SEK | -180.751% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 83.593% |
| Intervacc AB (publ) | 21.68 Million SEK | 46.181% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 89.054% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 66.28% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 56.313% |
| Corline Biomedical AB | 6.78 Million SEK | -71.866% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 80.983% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 27.604% |
| Aptahem AB (publ) | 8.99 Million SEK | -29.676% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 74.734% |
| Fluicell AB (publ) | 8.91 Million SEK | -30.881% |
| Biovica International AB (publ) | 34.76 Million SEK | 66.439% |
| Abliva AB (publ) | 16.78 Million SEK | 30.469% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 94.563% |
| 2cureX AB (publ) | 2.93 Million SEK | -297.547% |
| I-Tech AB | 16.2 Million SEK | 27.998% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.016% |
| Cyxone AB (publ) | 4.69 Million SEK | -148.573% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 12.455% |
| Biosergen AB | 5.08 Million SEK | -129.459% |
| Nanologica AB (publ) | 79.32 Million SEK | 85.291% |
| SynAct Pharma AB | 51.83 Million SEK | 77.49% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -46.786% |
| BioInvent International AB (publ) | 90.45 Million SEK | 87.1% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -124.603% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 93.575% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -550.39% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 8.443% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -60.716% |